{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:56:19Z","timestamp":1782863779733,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12185-026-04166-6","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:33:56Z","timestamp":1769776436000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent advances in the pathophysiology and treatment of plasma cell dyscrasias"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0300-378X","authenticated-orcid":false,"given":"Kazuhito","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"4166_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051558","volume":"15","author":"B Puertas","year":"2023","unstructured":"Puertas B, Gonz\u00e1lez-Calle V, Sobejano-Fuertes E, Escalante F, Queiz\u00e1n JA, B\u00e1rez A, et al. Novel agents as main drivers for continued improvement in survival in multiple myeloma. Cancers (Basel). 2023;15:1558.","journal-title":"Cancers (Basel)"},{"key":"4166_CR2","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36:1371\u20136.","journal-title":"Leukemia"},{"key":"4166_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13:125.","journal-title":"J Hematol Oncol"},{"key":"4166_CR4","doi-asserted-by":"publisher","first-page":"e716","DOI":"10.1016\/S2352-3026(22)00264-2","volume":"9","author":"GR Mohyuddin","year":"2022","unstructured":"Mohyuddin GR, Ahlstrom JM, Chmielewski CA, Sweeney NW, Molina TH, Cheung CS, et al. A survey on the patient perspective on cure in multiple myeloma. Lancet Haematol. 2022;9:e716\u20139.","journal-title":"Lancet Haematol"},{"key":"4166_CR5","first-page":"2420","volume":"109","author":"M Engelhardt","year":"2024","unstructured":"Engelhardt M, Kort\u00fcm KM, Goldschmidt H, Merz M. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica. 2024;109:2420\u201335.","journal-title":"Haematologica"},{"key":"4166_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821","volume":"9","author":"SF Cho","year":"2018","unstructured":"Cho SF, Anderson KC, Tai YT. Targeting b cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821.","journal-title":"Front Immunol"},{"key":"4166_CR7","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med"},{"key":"4166_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"4166_CR9","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"4166_CR10","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.2023022499","volume":"143","author":"H Lee","year":"2024","unstructured":"Lee H, Neri P, Bahlis NJ. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms. Blood. 2024;143:1211\u20137.","journal-title":"Blood"},{"key":"4166_CR11","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol. 2023;41:2087\u201397.","journal-title":"J Clin Oncol"},{"key":"4166_CR12","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","volume":"30","author":"CPM Verkleij","year":"2024","unstructured":"Verkleij CPM, O\u2019Neill CA, Broekmans MEC, Frerichs KA, Bruins WSC, Duetz C, et al. T-Cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma. Clin Cancer Res. 2024;30:3006\u201322.","journal-title":"Clin Cancer Res"},{"key":"4166_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023;41:711-725.e6.","journal-title":"Cancer Cell"},{"key":"4166_CR14","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"key":"4166_CR15","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"4166_CR16","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, et al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025;22:680\u2013700.","journal-title":"Nat Rev Clin Oncol"},{"key":"4166_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s12185-025-04045-6","volume":"122","author":"S Iida","year":"2025","unstructured":"Iida S, Ito S, Sunami K, Takamatsu H, Tsukada N, Hosen N, et al. JSH practical guidelines for hematological malignancies, 2023 III. Myeloma 1. Multiple myeloma (MM). Int J Hematol. 2025;122:465\u2013509.","journal-title":"Int J Hematol"},{"key":"4166_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100124","volume":"2","author":"T Kubicki","year":"2025","unstructured":"Kubicki T, Derman BA, Cooperrider JH, Pu\u0142a A, Barnidge D, Dytfeld D, et al. Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma. Blood Neoplasia. 2025;2:100124.","journal-title":"Blood Neoplasia"},{"key":"4166_CR19","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","volume":"392","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. N Engl J Med. 2025;392:1777\u201388.","journal-title":"N Engl J Med"},{"key":"4166_CR20","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1200\/JCO.23.02771","volume":"42","author":"MV Mateos","year":"2024","unstructured":"Mateos MV, Mart\u00ednez-L\u00f3pez J, Rodriguez Otero P, Gonz\u00e1lez-Calle V, Gonzalez MS, Oriol A, et al. Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance. J Clin Oncol. 2024;42:3247\u201356.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04166-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04166-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04166-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:10:39Z","timestamp":1782861039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04166-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4166"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04166-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K. Suzuki received personal fees from Janssen Pharmaceutical K.K., Sanofi, Bristol Myers Squibb, Ono Pharmaceutical Co., Ltd., Pfizer, and Takeda Pharmaceutical Company, outside the submitted work. Dr. Kazuhito Suzuki is editor of International Journal of Hematology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}